Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Travere Therapeutics ( (TVTX) ) is now available.
On September 10, 2025, Travere Therapeutics announced that the FDA has decided an advisory committee is no longer needed for the review of the supplemental New Drug Application for FILSPARI in treating FSGS. The application remains under review with a target action date of January 13, 2026. If approved, FILSPARI would be the first medication indicated for FSGS, a serious kidney disorder. The drug has shown promising results in reducing proteinuria in clinical trials, which is significant for patients as it lowers the risk of kidney failure. The studies supporting FILSPARI’s application demonstrated its efficacy and safety, with results published in the New England Journal of Medicine indicating a meaningful clinical benefit.
The most recent analyst rating on (TVTX) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.
Spark’s Take on TVTX Stock
According to Spark, TipRanks’ AI Analyst, TVTX is a Neutral.
Travere Therapeutics’ overall stock score is primarily influenced by its financial performance challenges, including high debt levels and negative cash flows. While the earnings call provided positive insights into product performance and strategic progress, the company’s valuation remains unattractive due to ongoing losses. Technical indicators suggest a neutral market sentiment, with no strong momentum in either direction.
To see Spark’s full report on TVTX stock, click here.
More about Travere Therapeutics
Travere Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for rare diseases. The company’s primary product, FILSPARI, targets kidney disorders such as focal segmental glomerulosclerosis (FSGS) and IgA nephropathy.
Average Trading Volume: 1,637,415
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.89B
For an in-depth examination of TVTX stock, go to TipRanks’ Overview page.